Research programme: ophthalmologic siRNA therapeutics - Sylentis

Drug Profile

Research programme: ophthalmologic siRNA therapeutics - Sylentis

Alternative Names: SYL-040003; SYL-054003

Latest Information Update: 12 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sylentis
  • Class Eye disorder therapies; Gene therapies; Small interfering RNA
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glaucoma; Ocular pain

Most Recent Events

  • 12 Jul 2016 Discontinued - Preclinical for Glaucoma in Spain (Topical)
  • 12 Jul 2016 Discontinued - Preclinical for Ocular pain in Spain (Topical)
  • 16 Nov 2011 Sylentis obtains a non-exclusive option to license InterfeRx™ siRNA technology from Alynlam Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top